1. Home
  2. BCO vs KYMR Comparison

BCO vs KYMR Comparison

Compare BCO & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCO
  • KYMR
  • Stock Information
  • Founded
  • BCO 1859
  • KYMR 2015
  • Country
  • BCO United States
  • KYMR United States
  • Employees
  • BCO N/A
  • KYMR N/A
  • Industry
  • BCO Oil Refining/Marketing
  • KYMR Medicinal Chemicals and Botanical Products
  • Sector
  • BCO Consumer Discretionary
  • KYMR Health Care
  • Exchange
  • BCO Nasdaq
  • KYMR Nasdaq
  • Market Cap
  • BCO 3.7B
  • KYMR 3.1B
  • IPO Year
  • BCO N/A
  • KYMR 2020
  • Fundamental
  • Price
  • BCO $87.59
  • KYMR $44.07
  • Analyst Decision
  • BCO Strong Buy
  • KYMR Strong Buy
  • Analyst Count
  • BCO 1
  • KYMR 16
  • Target Price
  • BCO $138.00
  • KYMR $58.94
  • AVG Volume (30 Days)
  • BCO 201.2K
  • KYMR 576.1K
  • Earning Date
  • BCO 08-06-2025
  • KYMR 08-06-2025
  • Dividend Yield
  • BCO 1.16%
  • KYMR N/A
  • EPS Growth
  • BCO 41.25
  • KYMR N/A
  • EPS
  • BCO 3.72
  • KYMR N/A
  • Revenue
  • BCO $5,022,500,000.00
  • KYMR $58,885,000.00
  • Revenue This Year
  • BCO $3.91
  • KYMR $58.26
  • Revenue Next Year
  • BCO $4.45
  • KYMR N/A
  • P/E Ratio
  • BCO $23.67
  • KYMR N/A
  • Revenue Growth
  • BCO 1.97
  • KYMR N/A
  • 52 Week Low
  • BCO $80.10
  • KYMR $19.45
  • 52 Week High
  • BCO $115.91
  • KYMR $53.27
  • Technical
  • Relative Strength Index (RSI)
  • BCO 37.00
  • KYMR 47.72
  • Support Level
  • BCO $92.59
  • KYMR $43.21
  • Resistance Level
  • BCO $94.55
  • KYMR $46.88
  • Average True Range (ATR)
  • BCO 1.78
  • KYMR 1.47
  • MACD
  • BCO -0.84
  • KYMR -0.40
  • Stochastic Oscillator
  • BCO 4.03
  • KYMR 21.03

About BCO Brinks Company (The)

The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provides BGS services and BGS activity in Latin American countries. It derives maximum revenue from North America segment.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Share on Social Networks: